[Diagnosis and therapy of rheumatoid arthritis]

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) treatment has advanced significantly with new potent drugs.
• Combination therapies involving biologics show promise for joint protection and inflammation control, even in advanced disease stages.
• Novel diagnostic markers, such as antibodies against cyclic citrullinated peptides (ACPA), enable earlier RA diagnosis.

Purpose of the Study:

• To review recent advances in rheumatoid arthritis therapy.
• To discuss the benefits and challenges of new therapeutic regimens.
• To highlight the importance of multidisciplinary collaboration in RA management.

Main Methods:

• Review of current literature on rheumatoid arthritis therapeutics.
• Analysis of combination therapy trials including biologics.
• Discussion of diagnostic advancements and side effect profiles of TNF inhibitors.
• Emphasis on the role of rheumatologist-orthopedic surgeon communication.

Main Results:

• Highly effective and early therapy for RA is more feasible due to new drugs.
• Combination therapies with biologics can protect joints and reduce inflammation in active destructive stages.
• Earlier diagnosis is supported by novel markers like ACPA.
• New therapeutic regimens are complex, costly, and associated with specific side effects, particularly from TNF inhibitors.

Conclusions:

• Modern RA management involves complex, expensive treatments requiring careful handling by rheumatologists.
• Understanding and managing side effects of biologics, especially TNF inhibitors, is crucial.
• Optimizing long-term RA patient care necessitates ongoing collaboration between rheumatologists and orthopedic surgeons.